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Abstract: Cyclodextrins (CDs) are naturally occurring cyclic oligosaccharides consisting of multiple
glucose subunits. CDs are widely used in host–guest chemistry and biochemistry due to their
structural advantages, biocompatibility, and ability to form inclusion complexes. Recently, CDs have
become of high interest in the field of medical imaging as a potential scaffold for the development of
a large variety of the contrast agents suitable for magnetic resonance imaging, ultrasound imaging,
photoacoustic imaging, positron emission tomography, single photon emission computed tomography,
and computed tomography. The aim of this review is to summarize and highlight the achievements
in the field of cyclodextrin-based contrast agents for medical imaging.
Keywords: medical imaging; contrast agents; α-cyclodextrin; β-cyclodextrin; γ-cyclodextrin; MRI;
PET; CT; SPECT; PAI
1. Introduction
Cyclodextrins (CDs) are chemically stable naturally occurring cyclic oligosaccharides consisting
of multiple glucose subunits connected by α-1,4 glycosidic bonds [1,2]. There are three main types
of CDs that contain six (α-CD), seven (β-CD), and eight (γ-CD) glucose subunits in a ring (Figure 1).
These cyclodextrin macromolecules are cone-shaped with a hydrophobic interior cavity and polar
exterior surface [3]. Due to their non-toxic nature [1,4–6] and water solubility [7–9], CDs became
widely used in various biomedical fields such as drug solubilization [7,10–12], drug delivery [8,13–17],
and nucleic acid transfer [18–20].
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Figure 1. Chemical structure of (a) α-cyclodextrin, (b) β-cyclodextrin, and (c) γ-cyclodextrin. 
Compared to other macrocyclic hosts, cyclodextrins are by far the most extensively used in host–
guest chemistry applications and medical imaging [21–25]. They tend to be the macrocycle of choice 
due to their structural advantages and robust ability to form inclusion complexes [21,26]. An 
inclusion complex is formed when a guest molecule, commonly a small drug, is partially or fully 
encapsulated inside the host’s interior cavity [1,3]. In the case of cyclodextrins, their preferred guest 
molecules tend to be hydrophobic, making them suitable for binding in the hydrophobic interior. 
Therefore, cyclodextrins possess the ability to form inclusion complexes with a wide variety of 
hydrophobic guest molecules [26–28]. Formation of inclusion complexes, or molecular encapsulation, 
can affect the physiochemical properties of the drug or molecule itself, such as solubility and rate of 
dissolution [3]. CDs are often exploited because of this property in addition to enhancing water 
solubility of water-insoluble molecules [3]. The exterior of cyclodextrin is predominantly hydrophilic 
due to the extensive hydrogen bonding network, making it a biocompatible agent for a wide range 
of applications [1–3,6–17]. These structural factors are largely why CDs are favored when 
synthesizing inclusion complexes. Electronics and thermodynamics both play a role in determining 
if a CD will form an inclusion complex with a guest molecule [1]. The driving force for inclusion 
complexation involves various noncovalent interactions such as desolvation, or removal, of water 
molecules from the interior cavity and formation of Van der Waals, hydrophobic, and hydrogen 
bonding interactions [29]. The major driving forces for cyclodextrin complexation are van der Waals 
interaction and hydrophobic interaction, whereas hydrogen bonding and electrostatic interaction 
mostly affect the conformation of a particular inclusion complex [29]. CD’s ability to form inclusion 
complexes with small organic molecules has pioneered the field of supramolecular chemistry. More 
recently, CDs have successfully been used to build various molecular architectures such as catenanes, 
rotaxanes, pseudorotaxanes, polyrotaxanes, and other molecular machines [30,31]. 
During the past few decades, cyclodextrins have become of interest as contrast agents and 
potential biosensors for different medical imaging modalities [32]. In the context of imaging, CDs 
have been used primarily as a scaffold to support and/or solubilize smaller molecules that produce 
or quench a signal for enhanced imaging. However, in a few cases, the unique supramolecular nature 
of the CD is essential in producing the signal for imaging. Examples of CD-containing constructs that 
can be imaged by a wide variety of modern imaging technologies are discussed herein. 
Magnetic resonance imaging (MRI) was the first imaging modality to utilize cyclodextrins as 
contrast agents [33]. CD-based MRI contrast agents produced contrast through the reduction in spin-
lattice relaxation (T1) time of the water protons. There are two different established methods of 
synthesis of CD-based MRI contrast agents: (1) host–guest interactions between CD cavity and metal–
organic complexes [33,34] and (2) by direct conjugation of CDs to the metal–organic complexes 
through the external hydroxyl groups of CD molecule [35,36]. The reduction in T1 relaxation for CD-
based contrast agents, and therefore their contrast, is substantially stronger compared to the metal–
organic complexes on their own [34,37]. 
Secondly, positron emission computed tomography (PET) utilizes CD-based molecular imaging 
probes [25]. The PET probes emit positron, which annihilates with a stationary electron from the 
surroundings producing two gamma-photons, which are detected [38]. The PET tracers based on CD 
can be divided in two classes. The first class contains CD-based nanoparticles (NPs) radiolabeled with 
either 64Cu [25] or 18F [39]. Another recently developed type of CD-based PET imaging agents contains 
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host–guest chemistry applications and medical imaging [21–25]. They tend to be the macrocycle
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form an inclusion complex with a guest molecule [1]. The driving force for inclusion complexation
involves various noncovalent interactions such as desolvation, or removal, of water molecules from the
interior cavity and formation of Van der Waals, hydrophobic, and hydrogen bonding interactions [29].
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surroundings producing two gamma-photons, which are detected [38]. The PET tracers based on CD
can be divided in two classes. The first class contains CD-based nanoparticles (NPs) radiolabeled
with either 64Cu [25] or 18F [39]. Another recently developed type of CD-based PET imaging agents
contains CD molecules conjugated to the p-NCS-benzyl-NODA-GA (NODAGA) chelator labeled
with 68Ga [40,41]. Followed by PET, the CD-based contrast agents were developed for single photon
emission computed tomography (SPECT). SPECT contrast agents were created by radiolabeling of
CD-based NPs either with 99mTc [42] or 125I [43].
Recently, CDs were applied as contrast agents for ultrasound (US) and photo-acoustic imaging
(PAI). The mechanism of contrast creation for US imaging relies on the substantial differences in the
acoustic impedances between the biological tissue and the CD-based agents [44]. The mechanism of
PA imaging is more complicated. The PA tracer absorbs the light with subsequent heating. Due to the
temperature increase, the contrast agent undergoes thermoelastic expansion resulting in emission of the
ultrasonic acoustic waves that can be detected by US receiver [45,46]. The developed CD photoacoustic
contrast agents absorbed the light in the infrared range [47–49].
Lastly, multiple studies were conducted to evaluate the performance of the CD-based contrast
agents for computed tomography (CT) [50–52]. All of the developments were focused on CD-based NPs
that contained metal atoms (Au, Yb, Dy) [50–53]. The presence of the element with high atomic number
rises up the X-ray absorption coefficient yielding to the contrast increase. These CD-based contrast
agents demonstrated better performance compared to conventional iodine-based CT agents [50,51].
The purpose of this review is to provide an update on recent developments in CD-based contrast
agents. A comparison of the developed contrast agents to the clinically available are presented as well
as a comparison between different CD-based agents.
2. CD-Based Contrast Agents for MRI
MRI was the first medical imaging modality that began to develop CD-based contrast agents.
The vast majority of the developed CD-based contrast agents reduce T1 relaxation of the surrounding
protons and were used to produce substantial contrast on T1-weighted images. Nevertheless, several
studies demonstrated the potential of T2 CD-based contrast agents as well. An overall summary of the
achievements and developments in CD-based MRI contrast agents and molecular imaging probes is
presented in detail below.
Due to the wide disfavor of traditional MRI probe modalities, mainly consisting of
diethylenetriamine pentaacetic acid (DTPA) and dodecane tetraacetic acid (DOTA)-derived small
molecule Gd(III) complexes, the continuous development and synthesis of innovative contrast agents is
needed [54]. Cyclodextrin-based MRI contrast agents have gained notoriety in the last two decades and
prove to be viable, robust candidates as potential MRI sensors for biomedical imaging [54]. In addition
to their high biocompatibility and ability to form inclusion complexes, their large molecular weights,
ease of functionalization and conjugation, and multivalent loading capacity make them well-suited
as a new class of paramagnetic macromolecules [35,55,56]. CDs have proved to enhance contrast,
sensitivity, and diagnostic imaging time [35]. This is attributed mainly due to their large molecular
weights, which allow for longer and tunable rotational times [35,54].
2.1. Contrast Agents Based on Host–Guest Complexation between CDs and Metal–Organic Chelates
2.1.1. In Vitro Studies of the Host–Guest CD-Based MRI Contrast Agents
The genesis of CD-based MRI contrast agents occurred in 1991 when Aime et al. [33] applied
Freed’s theory [57] to predict that the relaxation rates of the solvent protons increase when the
paramagnetic ion or complex is bound to a macrocycle. This principle became a fundamental
base for the future development of CD-based MRI contrast agents. Aime et al. reported
numerous results for the inclusion complexes formation between CD and gadolinium chelates
such as DOTA and DTPA. Host–guest interaction is dependent on internal cavity size: α-CD did
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not demonstrate host–guest interaction, while β-CD non-covalently bonded with DOTA/DTPA
with significant increase in proton relaxivity in vitro (reciprocal spin-lattice relaxation time (1/T1))
observed for both β-CD-DOTA and β-CD-DTPA contrast agents [33]. Subsequent studies utilizing
Gd(III)-bis(benzylamide)diethylenetriaminepentaacetic acid (BBA-DTPA) [34], gadolinium (III)
3,6,9,15-tetraazabi-cyclo[1,3,9]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA) complexed with
poly-β-CD [58], and DOTA-benzyloxymethyl (DOTA(bom)3) [59] demonstrated increasing water
proton relaxivity due to the larger quantity of paramagnetic complexes accumulating in the region of
interest due to interactions with a β-CD polymers [59]. The relaxivity of the developed poly- β-CD
contrast agents exceeded up to six times the clinical analogues (r1 = 61 mM−1s−1) [59]. Furthermore,
the results of modified Gd(III)-PCTA in blood serum suggested the possibility of application of this
developed CD-based contrast agent in MRI angiography [58]. Despite such promising results, the
relaxation measurements were conducted at 20 MHz NMR spectrometer at 0.5 T magnetic field far
below the clinical MRI magnetic fields (1.5 or 3.0 T).
Larger CD-based NPs have also been the subject of recent research. These NPs have the
potential for lower toxicity [60] compared to Gd-CD-based contrast agents. Examples of a proposed
β-CD-based Gd-loaded NPs include a supramolecular assembly between DO3A-based gadolinium
chelate (conjugated to adamantane through an acetamide spacer), poly-β-CD, and modified dextran [60]
and cleavable β-CD-based Gd(III)-loaded nanocapsules, a promising agent as a redox-sensitive MRI
contrast agent [61]. Besides toxicity reduction in Gd chelates, the proposed NPs are utilized the
concept of further increasing of the number of Gd(III) atoms per unit of contrast agent resulting in
increasing relaxivities.
2.1.2. In Vivo Imaging of the Host–Guest CD-Based Contrast Agents
The performance of some CD-based MRI imaging agents has been evaluated in vivo. Lahrech et al.
demonstrated imaging of C6 glioma rats using a Gd-α-CD complex to quantify cerebral blood
volume [62]. Although performance of Gd-α-CD contrast agents was significantly better compared
to Gd-DOTA in terms of relaxation rates (r1 = 7.3 mM−1s−1 at 9.4 T), the developed supramolecular
agent did not accumulate in tumors and almost no enhancement was observed on T1-weighted images
during the first hour after Gd-α-CD injection. On the contrary, the CBV fraction was successfully
measured using rapid steady state T1 method and Gd-α-CD contrast agent.
More advanced CD-based contrast agents were demonstrated by Sun et al. who created
a supramolecular complex between bridged bis(permethyl-β-cyclodextrin)s with Mn-porphyrin
bearing polyethylene glycol side chains (Mn-TPP) [63]. Mice injected with this supramolecular
polymer demonstrated strong contrast observed in the blood, kidneys, and bladder (Figure 2) [63].
A supramolecular polymer built using the non-covalent interaction between Mn(II)-TPP and bridged
tris(permethyl-β-CD)s resulted in a longitudinal relaxivity only 7% higher compared to previously
developed Mn(II)-containing linear polymer [63,64].
Work by Feng et al. conducted on CD-based NPs as MRI contrast agents demonstrated neodymium
doped NaHoF4 NPs as T2 imaging agents cultured with human mesenchymal stem cells injected into
the brain hemisphere of nude mice. This combination of CD-based contrast agents and stem cells [23]
supports the idea of using stem cells as an MRI contrast agent carrier. Furthermore, due to the high
relaxivity of the developed probe (r2 = 143.7 mM−1s−1 at 11.7 T) [23], use of the developed contrast
agent will be beneficial for ultrahigh field MRI imaging, since the transverse relaxivity increases highly
with the magnetic field strength [23,65,66].
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2.1.3. In Vivo Tumor Imaging 
Imaging of cancer is one of the hot topics in modern medical imaging field. Despite the 
numerous developed contrast agents discussed above, only Zhou et al. used multiple β-CDs attached 
to a polyhedral oligomeric silsesquioxane nano globule at a targeted nano globular contrast agent 
Figure 2. (a) Molecular structure of Mn(II)-TPP and bridged bis(permethyl-β-CD)s polymer.
(b) Representative 2D coronal T1-weighted MR images of the mice at 2, 5, 10, 20, and 25 min
after intravenous injection of Mn(II)-TPP/bridged β-CD magnetic resonance imaging (MRI) contrast
agents at 0.03 mmol of Mn/kg [63]. The images are reprinted with permission from publisher [63].
2.1.3. In Vivo Tumor Imaging
Imaging of cancer is one of the hot topics in modern medical imaging field. Despite the numerous
developed contrast agents discussed above, only Zhou et al. used multiple β-CDs attached to a
polyhedral oligomeric silsesquioxane nano globule at a targeted nano globular contrast agent from
host–guest assembly for magnetic resonance cancer molecular imaging [67]. The host–guest contrast
agent bonds to αvβ3 integrinin 4T1 malignant breast tumor through cyclic RGDfK peptide and
gives greater contrast enhancement, due to the αvβ3 that is overexpressed in tumors (Figure 3a–c).
This designed contrast agent produced superior contrast and signal enhancement compared to the
clinically used Gd-based ProHance and non-targeted control cRAD-POSS-bCD-(DOTA-Gd)-Cy5
Molecules 2020, 25, 5576 6 of 27
contrast agent. Molecular structure of cRGD-POSS-βCD-(DOTA-Gd)-Cy5 imaging agent is shown
on Figure 3d.
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2.2. Direct Labeling of the CD Molecules 
Another approach of synthesis of CD-based contrast agents for MRI imaging purposes is to 
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We refer to this method as direct labeling of CD molecules. The key advantage of this approach is the 
Figure 3. Magnetic resonance molecular imaging with cRGD-POSS-βCD-(DOTA-Gd)-Cy5 in
mice bearing 4T1-Luc2-CFP tumor xenografts. The representative 2D axial fat-suppressed
T1-weighted spin-echo MRI images before and at 5, 15, and 30 min post-injection of ProHance (a),
cRAD-POSS-bCD-(DOTA-Gd)-Cy5 (b), and cRGD-POSS-bCD-(DOTA-Gd)-Cy5 (c) at 0.1 mmol-Gd/kg.
The injection of cRGD-POSS-βCD-(DOTA-Gd)-Cy5 creates superior signal enhancement in tumor
region. The images are reprinted with permission from publisher [67]. (d) Molecular structure of the
developed cR -P SS-β -( T - d)- y5 contrast agent.
2.2. irect Labeling of the olecules
nother approach of synthesis of -base contrast agents for I i aging p rposes is to
conj gate etal–organic (III)-containing co plexes to the olecule through covalent bonds.
e refer to this etho as irect labeling of olec les. he key a vantage of this a roach is the
availability of CD cavity for host–guest interaction with other molecules that can be effectively used
for drug delivery study and imaging of molecular interactions.
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Synthetically, modifying CDs in order to meet the criteria of an ideal contrast agent can be
summarized by three key components: having a point of functionalization to attach the chelating group,
designing a rigid linker in order to slow local movements, and lastly, conjugation of the macrocyclic
complex in order to encapsulate multiple lanthanide chelates—thus, overall enhancing MRI signal,
while improving overall stability and relaxivity profiles [35,54–56,68].
Various synthetic approaches have been explored, which demonstrates CD’s ability to be
functionalized and conjugated in a robust fashion dependent on the desired application(s) [35,54–56,68].
Bryson et al. synthesized a monodisperse β-CD Click cluster containing seven paramagnetic chelates
encompassing two water exchange sites [35]. Using Click chemistry, an alkyne-functionalized dendron
was reacted with the per-azido-β-CD to yield the desired product (Figure 4). Using similar methods,
Champagne et al. recently reported the synthesis of a different β-CD MRI probe containing seven
iminodiacetate arms connected at the C6-position of β-CD by a triazole-based linker following a
copper(I)-mediated 1,3-dipolar cycloaddition [54]. In addition, CDs can be differentially conjugated
to produce multifunctional probes. Kotková et al. synthesized a novel bimodal fluorescence/MRI
probe using a β-CD scaffold [55]. β-CD was labeled first using fluorescein isothiocyanate (FITC) and
subsequentially with an isothiocyanate derivative containing a DOTA-based ligand [55]. The rigidity
of the linker between the CD and the Gd-containing ligand plays an important role in increasing
TR, thus enhancing the overall MRI signal [35,55]. Additionally, multifunctional NPs have been
modified using an asymmetrically functionalized β-CD-based star copolymer by conjugating β-CD
using doxorubicin (DOX), folic acid (FA), and DOTA-Gd moieties [54]. Similar to the work of
Bryson et al. [35] and Champagne et al. [54], the key conjugation method used was azide-alkyne
Huigsen cycloaddition, creating rigid triazole linkers.
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2.2.1. In Vitro Development 
Skinner et al. demonstrated the first labeling of CD macrocycle with a Gd(III) chelate albeit the 
CD cavity was still used for non-covalent binding to another Gd(III) chelate in order to increase the 
proton relaxivity. [69]. Relaxivity of this complex increased when it was bound noncovalently to 
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Figure 4. Multivalent β-CD “Click cluster”, containing seven paramagnetic chelating groups, each with
two water exchange sites linked via triazole-based linkers. The β-CD “Click cluster” was synthesized
from per-azido-β-CD precursor and conjugated using the well-established Huigsen cycloaddition
reaction. Figure adapted from Bryson et al. with permission from publisher [35].
2.2.1. In Vitro Development
Skinner et al. demonstrated the first labeling of CD macrocycle with a Gd(III) chelate albeit the CD
cavity was still used for non-covalent binding to another Gd(III) chelate in order to increase the proton
relaxivity. [69]. Relaxivity of this complex increased when it was bound noncovalently to another
gadolinium complex with the addition of two phenyl moieties.
Bryson et al. created a contrast agent with a ten-fold increase in relaxivity at 9.4 T
compared to clinically available Magnevist by labeling of per-azido-β-cyclodextrin core with seven
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diethylenetriaminetetraacetic acid (DTTA) Gd(III) chelates [35]. This development can be attributed
to the increased Gd(III) ions per molecule and further increase in relaxivity due to conjugation to
the macrocycle. In addition to the high relaxivity, unoccupied cavity of β-CD makes the developed
contrast agent an excellent host scaffold to functionalize through noncovalent assembly with biological
receptor-specific targets.
Bimodal MRI-fluorescence probes were demonstrated by Kotkova et al. [55] who combined
a DOTA-based ligand with fluorescein functionality to simultaneously obtain fluorescence and
MR images. Although the developed CD-based agent was studied in vitro, the benefit of this
scaffold for MRI visualization under in vivo conditions was assumed due to its low cytotoxicity
and high cell uptake. Fredy et al. developed cyclodextrin polyrotaxanes as a highly modular
platform for an imaging agent [70]. Selectively functionalized cyclodextrins with a Gd(III) complex
or BODIPY fluorescent tag were put on to a polyammonium chain to form polyrotaxanes. From
this, polyrotaxanes could be assembled with fluorescent CDs and CDs with dia- or paramagnetic
lanthanide complexes. Each threaded cyclodextrin was molecularly defined, which is an advantage
over statistical post-functionalization of CD-polyrotaxanes. In vitro studies demonstrated that the
Gd-bearing polyrotaxanes have relaxivities that are five times higher than Gd-DOTA, which makes
them effective contrast agents for MRI applications [70].
NPs fabricated using biological macromolecules have been demonstrated by both Liu et al. [68]
and Su et al. [71]. Liu designed pH disintegrable β-CD-based micellar NPs, while Su reported star-like
dextran wrapped superparamagnetic iron oxide NPs. Both groups reported dual effects: an imaging
contrast agent and cytotoxicity to HeLa cells at high concentrations, making these molecules both
imaging probes and potential chemotherapeutics agents. Later, the synthesis of the contrast agent that
affects the spin-spin (T2) relaxation was suggested by conjugating β-CD to magnetic NPs [72].
2.2.2. In Vivo Imaging of CD-Based MRI Contrast Agents Based on the Direct Labeling of CD Cavity
In vitro studies have paved the way for a number of groups to demonstrate CD-based MRI contrast
agents in vivo. Vascular imaging has long been a molecular imaging goal allowing investigators
the ability to image the vasculature with high contrast. The G2/MOP–DTPA–Gd contrast agents
synthesized from polyester dendrimers with β-CD core have been demonstrated with high yield
and fast synthesis while providing for 2.7 times the relaxivity of Magnevist (DTPA-Gd) [24]. This
contrast agent is rapidly hydrolyzed at the pH of 7.4 in the presence of esterase and slowly hydrolyzed
at an acidic pH. The superior signal enhancement in vivo was observed following 0.1 mM Gd/kg
injection (Figure 5a) and was significantly higher compared to Magnevist (Figure 5b) Furthermore,
the G2/MOP–DTPA–Gd contrast agent (Figure 5c) did not show tissue retention, making the ideal
blood pool and kidney imaging agent.
Zhou et al. synthesized Gd(III)-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-β-
CD/Pluronic polyrotaxane contrast agent [73]. Interestingly, Gd-DO3A-HPCD/Pluronic polyrotaxane
construct circulated for more than 30 min in the living mouse and caused about 100-fold vascular
enhancement when compared to the monomeric form (Figure 6a). Furthermore, the polyrotaxane
derivative showed a much higher signal enhancement after 5 min in the heart than the
monomeric form but underwent rapid elimination by renal filtration, preventing blood enhancement.
Thus, the Gd(III)-DO3A-HPCD/Pluronic polyrotaxane (Figure 6b) is a promising contrast agent,
which enables higher anatomic detail of blood vessel organization.
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2.2.3. In Vivo Imaging of Cancer
Cancer metastasis is the final insult leading to patient mortality. The early detection of metastasis
is therefore a primary concern in the field of oncology. CD-based MRI contrast agents hold promise
for the imaging of metastasis. Although CD-based contrast agents have yet been clinically tested,
a number of groups have demonstrated these contrast agents in mammalian models.
Zhou et al. [74] reported the enhancement of MRI of liver metastases with a zwitterionized
biodegradable dendritic CD-based contrast agent. Traditionally, the sensitivity in the liver for MR
imaging of metastases is low due to the accumulation of the contrast agent in the Kupffer cells and
hepatocytes instead of cancer cells. Zhou et al. used a novel dendritic contrast agent with β-CD
core and the net size of 9 nm. The developed dendritic contrast agent reduces background signals
in the liver significantly by avoiding being uptakes by hepatocytes and Kupffer cells through the
zwitterionization, while increasing the signal in tumors through the enhanced permeability and
retention effect. This CD-based zwitterionized dendritic contrast agent also showed shorter Gd(III)
retention in all organs and tissues, because it could degrade into small fragments.
Zhang et al. developed polyethyleneimine- β-CD (PEI-β-CD) as a novel vector for carrying ferritin
gene modified by alpha-fetoprotein promoter [75] to create a highly specific endogenous T2 contrast
agent for hepatocellular carcinoma. In vitro T2-weighted and T2*-weighted MRI was used to examine
the effect of ferritin heavy gene transfection. Zhang et al. observed the significant T2/T2*-induced
MRI signal decay (up to 40%) from the BEL-7402 hepatocellular carcinoma cells treated with the
developed PEI-β-CD/ferritin gene. Therefore, it was proposed that the ferritin gene carried by PEI-
β-CD has a high potential to be used for early-stage MRI detection as an endogenous contrast agent
for hepatocellular carcinoma imaging.
Gd (III) oxide NPs coated with folic acid functionalized poly (β-CD-co-pentetic acid)
(Gd2O3@PCD-FA) as a biocompatible targeted nano-contrast agent was proposed by Mortezazadeh
et al. [76]. Mortezazadeh et al. observed that Gd2O3@PCD-FA demonstrated significantly higher
r1 and r2 relaxivities at 3T (r1 = 3.95 mM−1s−1; r2 = 4.6 mM−1s−1) than Gd(III)-DOTA. On the
other hand, the measured relaxivities were lower compared to the pure Gd2O3 (r1 = 4.86 mM−1s−1;
r2 = 5.97 mM−1s−1) due to the reduced water accessibility to Gd2O3 core in Gd2O3@PCD-FA. In order
to study the performance of the developed NPs in vivo, the Gd2O3@PCD-FA contrast agent has been
evaluated in the animal tumor model. Maximization of CNR was observed in 1h post-injection of
the Gd2O3@PCD-FA contrast agent. Interestingly, Gd2O3@PCD-FA NPs demonstrated almost no
cytotoxicity after 12 and 24 h administering to MCF-10A human normal breast cell lines.
Han et al. developed a hypoxia-targeting dendritic MRI contrast agent based on internally
hydroxy dendrimer (IHD) with β-CD core [77]. The disturbance of the zwitterionic surface reduces
unspecific cellular uptake by normal cells. In vivo imaging of an orthotopic breast tumor in mice
injected with the developed contrast agent showed the maximization of CNR in 1 h post-injection. Han
et al. observed CNR reaching the level of 10, remaining constant during the second hour, and slightly
decaying 3 h post-injection.
2.3. Cyclodextrin-Based Contrast Agents for Hyperpolarized MRI
Although molecular imaging using MRI is challenging due to the lack of sensitivity of this imaging
modality [78,79], progress has been made with the development of hyperpolarized (HP) MRI [79,80].
HP MRI utilizes the advantage of a metastable state with spin population excess significantly larger
compared to the thermal equilibrium state [81]. Hyperpolarization of noble gases (such as 3He and
129Xe) is conducted via spin exchange optical pumping (SEOP), whereas polarization of 13C or 1H
containing molecules is created through dynamic nuclear polarization (DNP) [82–85].
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2.3.1. Hyperpolarized 13C CD-Based Contrast Agents
Due to the high signal enhancement, molecular imaging using HP 13C-containing molecule
becomes possible. β-CD was used to create a contrast for HP 13C MRI [86]. Keshari et al. showed
that the host–guest interaction between a β-CD cavity and HP benzoic acid substantially decrease the
T1 relaxation of both HP 13C nuclei resulting in negative image contrast (decrease in signal intensity)
induced by the presence of supramolecular cage (Figure 7). Based on this result, the authors proposed
that similar mechanism of the negative contrast can be used to study the interaction of ligand–receptor
pairs in vivo.
Molecules 2020, 25, x FOR PEER REVIEW 11 of 27 
 
relaxation of both HP 13C nuclei r sulting in egative ima  c trast (decrease in signal intensity) 
induced by the presence of supramolecular ca  re 7). Based on this result, the autho s roposed 
that similar mechanism of  negative contrast can be used to study the interaction of ligand–
receptor pairs in vivo. 
 
Figure 7. In vitro experiment at 14T demonstrating the potential application of β-CD as a contrast 
agent for hyperpolarized (HP) 13C MRI. (a) Proton gradient echo image demonstrating the position of 
phantoms with a different concentration of β-CD (0–10 mM). The HP 13C imaging was performed 
after the administration of 2.5 mM HP [1-13C] benzoic acid. It can be seen that the MRI signal 
decreases with β-CD concentration. (b) Relative MRI 13C signal dependence on β-CD concentration 
[86]. The images are reprinted with permission from publisher [86]. 
DNP was used to create a CD contrast agent for DNP HP MRI [87]. Caracciolo et al. observed 
the polarization level of 10%. Unfortunately, the T1 relaxation of β-CD protons was equal to 1s at 300 
K, which made HP β-CD inapplicable for molecular imaging purposes. On the other hand, HP β-CD 
can be of interest in the fields, which require the production of strong 1H NMR signal from CD 
molecules [87]. Following this work was the hyperpolarization of methylated β-CD [88]. The 
methylation has been conducted using 13CH3I, which enriched the potential contrast agent with 13C 
and 1H nuclei. Methylated β-CDs underwent DNP and polarization levels of 7.5 and 7% were 
achieved for 1H and 13C, respectively. The proton T1 relaxation times were found to be similar to those 
published in [87]; however, the T1 relaxation time of 13C nuclei was equal to 3.3 and 4.9 s for fully 
methylated β-CDs and partially methylated β-CDs, respectively. These relaxation times allow further 
application of HP β-CD as contrast agents in the molecular imaging field. In addition, authors 
demonstrated the method of further increasing relaxation times [88]. 
2.3.2. CD-Based Molecular Probes for Hyperpolarized 129Xe MRI 
Current studies of molecular imaging with HP 129Xe MRI utilizes hyperpolarized chemical 
exchange saturation transfer (HyperCEST) [89,90]. The HyperCEST effect relies on a constant 
chemical exchange between the dissolved HP 129Xe nuclei in the solution and supramolecular host 
that can effectively encapsulate 129Xe [79]. Following selective depolarization of the 129Xe nuclei 
encapsulated in the supramolecular cage, the decrease in the dissolved phase 129Xe MRI signal can be 
observed as a result of the exchange dynamic [79,89]. 
The interaction between HP 129Xe and the α-CD cavity was studied for the first time in 1997 [91]. 
Authors observed that spin polarization induced nuclear Overhauser effect (SPINOE) and related 
transfer of nuclear polarization to the α-CD protons [91]. However, this approach did not become 
widely used in the field of molecular imaging using HP 129Xe. 
CD-based contrast agents for HyperCEST molecular imaging became of interest recently. The 
first detection of HyperCEST effect using α-CD-based molecules was achieved from the α-CD 
pseudorotaxane complex with five carbon diethylimidazolium bar in aqueous solution [92]. The 
observed HyperCEST depletion was equal to 30%, which is significantly smaller compared to other 
molecular imaging probes [89,93]. The first β-CD-based molecular imaging probe for HyperCEST 
detection has been developed recently [94]. The HyperCEST contrast agent was realized as 
cucurbit[6]uril-based rotaxane in which β-CDs played the role of a stopper. Although rotaxane 
interaction with 129Xe was through cucurbit[6]uril cavity and no HyperCEST effect was observed from 
β-CDs, the presence of β-CDs was required in order to increase the solubility of the end groups [94]. 
Figure 7. In vitro experiment at 14T demonstrati t e potential ap lication of β-CD as a contrast
agent for hyperpolarized (HP) 13C MRI. (a) Proton gradient echo image demonstrating the position of
phantoms with a different concentration of β-CD (0–10 mM). The HP 13C imaging was performed after
the administration of 2.5 mM HP [1-13C] benzoic acid. It can be seen that the MRI signal decreases with
β-CD concentration. (b) Relative MRI 13C signal dependence on β-CD concentration [86]. The images
are reprinted with permission from publisher [86].
DNP was used to create a CD contrast agent for DNP HP MRI [87]. Caracciolo et al. observed
the polarization level of 10%. Unfor unately, the T1 relaxation of β-CD protons was qual to 1s
at 300 K, which made HP β-CD inapplicable for molecular imaging purp ses. On the other hand,
HP β-CD can be of interest in the fields, which require the production of strong 1H NMR signal
from CD molecules [87]. Following this work was the hyperpolarization of methylated β-CD [88].
The methylation has been conducted using 13CH3I, which enriched the potential contrast agent with
13C and 1H nuclei. Methylated β-CDs underwent DNP and polarization levels of 7.5 and 7% were
achieved for 1H and 13C, respectively. The proton T1 relaxation times were found to be similar to
those published in [87]; however, the T1 relaxation time of 13C nuclei was equal to 3.3 and 4.9 s for
fully methylated β-CDs and partially methylated β-CDs, respectively. These relaxation times allow
further application of HP β-CD as contrast agents in the molecular imaging field. In addition, authors
demonstrated the method of further increasing relaxation times [88].
2.3.2. CD-Based Molecular Probes for Hyperpolarized 129Xe MRI
Current studies of molecular imaging with HP 129Xe MRI utilizes hyperpolarized chemical
exchange saturation tr nsfer (HyperCEST) [89,90]. The HyperCEST effect relies on a constant chemical
exchange between the dissolved HP 129Xe nuclei in the solution and supramolecular host that can
effectively encapsulate 129Xe [79]. Following selective depolarization of the 129Xe nuclei encapsulated
in the supramolecular cage, the decrease in the dissolved phase 129Xe MRI signal can be observed as a
result of the exchange dynamic [79,89].
The interaction between HP 129Xe and the α-CD cavity was studied for the first time in 1997 [91].
Authors observed that spin polarization induced nuclear Overhauser effect (SPINOE) and related
transfer of nuclear polarizatio to the α-CD protons [91]. However, this approach did not become
widely used in the field of molecular imaging using HP 129Xe.
CD-based contrast agents for HyperCEST molecular imaging became of interest recently.
The first detection of HyperCEST effect using α-CD-based molecules was achieved from the
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α-CD pseudorotaxane complex with five carbon diethylimidazolium bar in aqueous solution [92].
The observed HyperCEST depletion was equal to 30%, which is significantly smaller compared
to other molecular imaging probes [89,93]. The first β-CD-based molecular imaging probe for
HyperCEST detection has been developed recently [94]. The HyperCEST contrast agent was realized
as cucurbit[6]uril-based rotaxane in which β-CDs played the role of a stopper. Although rotaxane
interaction with 129Xe was through cucurbit[6]uril cavity and no HyperCEST effect was observed from
β-CDs, the presence of β-CDs was required in order to increase the solubility of the end groups [94].
Finally, the HyperCEST effect from γ-CD-based pseudorotaxane was observed after the
complexation of γ-CD with bisimidazolium guest [95]. Although γ-CD cavity is too large to sufficiently
interact with HP 129Xe, the cavity size can be decreased by threading it with a long alkyl chain.
Threading these guest molecules through the cavity of γ-CD reduces the cavity size in order for
adequate HP 129Xe binding to occur, thus making it suitable for HyperCEST detection (Figure 8a).
Potentially, this same concept can be applied for any supramolecular cage with a reasonably large
cavity. The HyperCEST effect detected from γ-CD-based pseudorotaxanes was equal to 47.5% on
average, which makes them interesting candidates for further application in vivo [95]. The main
advantage of the HyperCEST contrast agents based on pseudorotaxane architecture over the other
studied HP 129Xe hosts is the ease synthesis and of functionalization of the pseudorotaxanes.
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In addition, γ-CD pseudorotaxane complexes prove to be a sufficient paradigm for HP 129Xe MRI.
The synthesis of the threads proceeds in one step and can be functionalized with different terminal
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end groups as well as different chain lengths. The 8- and 10-carbon alkyl chains were functionalized
with ethylimidazoliums (Figure 8b), strategically used to enhance water solubility of the inherently
hydrophobic alkyl chain [95]. The γ-CD pseudorotaxane was comparable to that of CB6, a known
xenon cage that has been responsive to in vivo HP 129Xe MRI [80]. Similar to CB6, the maximum
HyperCEST depletion for γ-CD pseudorotaxanes was present when the samples were irradiated at
a frequency of +128 ppm [95]. γ-CD pseudorotaxanes exhibited binding on the order of 103 at 1:1
host–guest complexation, proving to be sufficient association for HP 129Xe. In addition, binding proved
to be two magnitudes of order lower in fetal bovine serum, indicating that this system would work
sufficiently as a potential biosensor in vivo [95].
3. CDs-Based Contrast Agent for Ultrasound Imaging and Photoacoustic Imaging
In addition to MRI contrast agents, CDs have been used for ultrasound (US) imaging. The first
approach of synthetizing the potential contrast agent was developed by Cavalieri et al., in 2006 [96].
Air-filled polymer microbubbles functionalized with β-CDs were used as a source for contrast.
The contrast originates from significant difference between acoustic impedance of tissue and air
encapsulated inside of a microbubble. Cavalieri et al. found that conjugating microbubbles to β-CD
preserves them from random coil to α- helix conformation transition. In addition, due to the presence
of β-CD, these contrasts allow hosting molecules with hydrophobic features [96].
After nearly a decade of inactivity, the second attempt of using a β-CD-based contrast agent
for US imaging was made in 2015 [44]. The authors demonstrated use of a perfluorinated FC-77/
β-CD complex. A visible blurring of signal from FC-77/β-CD caused by a disruption of the inclusion
complexes under US was detected [44].
Another US medical imaging modality that utilized CD-based contrast agents was PAI. The first
CD-based contrast agent was synthetized by surface modification of oleic-acid (OA) stabilized
upconversional NPs (UCNPs) NaYF4:Yb3+, Er3+ with α-CD [49]. α-CD formed an inclusion complexes
with an OA yielding to luminescence quenching of UCNPs and production of a strong PA signal
instead (Figure 9a). Cytotoxicity studies demonstrated no toxicity of α-CD/UCNPs contrast agents.
Following in vitro imaging (Figure 9b), the first PAI in a living mouse was conducted using 980 nm
excitation laser. These results demonstrated the ability of α-CD/UCNPs to be an efficient PAI contrast
agent for diagnostic purposes [49].
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mice model of PJI. Wang et al. found that conjugation of ICG to β-CD improves its PA signal 
generation. Although the PAI signal increase was not significant with β-CD-ICG contrast, it still 
demonstrated the ability to serve as a contrast agent for non-invasive diagnostic of PJI [48]. 
Yu et al. recently developed a CD-based PAI contrast agent sensitive to tumor environment [47]. 
Gold NPs (AuNP) were modified initially with pyridine-2-imine-terminated single stand DNA via 
gold-thiol bonds, and α-CDs were capped on the end of DNA through hydrophobic interaction with 
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An effective PAI agent for imaging prosthetic joint infection (PJI) [48] was demonstrated by
conjugation of β-CD to indocyanine green (ICG). The β-CD-ICG PAI agent was demonstrated in the
mice model of PJI. Wang et al. found that conjugation of ICG to β-CD improves its PA signal generation.
Although the PAI signal increase was not significant with β-CD-ICG contrast, it still demonstrated the
ability to serve as a contrast agent for non-invasive diagnostic of PJI [48].
Yu et al. recently developed a CD-based PAI contrast agent sensitive to tumor environment [47].
Gold NPs (AuNP) were modified initially with pyridine-2-imine-terminated single stand DNA via
gold-thiol bonds, and α-CDs were capped on the end of DNA through hydrophobic interaction with
CD’s cavity. The α-CD-AuNP agent produced no PA signal under neutral pH conditions, but upon
entering the tumor, α-CDs separate from the DNA ends due to reduction in non-covalent forces.
This study demonstrated that a developed α-CD-AuNP contrast agent can be successfully used as a
tumor-selective theranostic agent [47].
4. Radiolabeled CD-Based Contrast Agents
PET and SPECT are imaging modalities that require probe radiolabeling to produce tomographic
images. These modalities have superior sensitivity and deeper tissue penetration compared with
luminescence-based imaging and MRI [97]; they require lower dose of imaging agent for functioning.
However, the application of PET/SPECT tracers is limited to the half-life of radiolabeled isotopes and
biodistribution in the living organism.
The first demonstration of the CD-based PET molecular imaging probe was done by Bartlett et al.,
in 2007 [25]. CD-containing NPs were studied as delivery agents for transferrin (Tf)-targeted delivery
to tumors of siRNA molecules. Nontargeted and Tf-targeted siRNA NPs were synthetized by using
cyclodextrin-containing polycation. One percent of the targeted NPs containing adamantane-PEG
molecules on the surface were modified with Tf. Si-RNA were conjugated with DOTA to the 5′ end
with further 64Cu labeling [25]. MicroPET revealed negligible impact of the attachment of the Tf
targeting ligand to the NPs on biodistribution. Unfortunately, nearly identical tumor localization
kinetics of both targeted and nontargeted 64Cu-DOTA-siRNA NPs were observed; tumor accumulation
was also similar at 1 day after injection (≈1% ID/cm3). However, bioluminescent imaging showed the
intracellular localization and functional activity of siRNA delivered by Tf-targeted NPs in the tumor
cells 1 day after injection.
Interestingly, the presence of CD in therapeutic compounds allows radio isotopic labelling for
PET imaging of the drug circulation. In vivo biodistribution of the IT-101, clinically developed drug
for cancer treatment, in mice with Neuro2A tumors was studied by Schluep et al. [98]. IT-101 contains
molecule drug camptothecin (CPT) conjugated with β-CD based polymers (CDP), which acts as
a carrier system for active molecule. The CDP site was labeled with 64Cu through attaching of
DOTA complex for microPET imaging; the obtained nanoparticle was similar to the IT-101 structure.
Plasma pharmacokinetics of 64Cu-IT-101 ere studied at 1, 4, and 24 h after injection with microPET/CT.
It was shown that a low-molecular-weight fraction cleared rapidly through kidneys due to biphasic
elimination profile, whereas remaining NPs circulated with a terminal half-life of ≈13 h. Biodistribution
of IT-101 was examined at 24 h after administration; the highest tissue concentration was found in the
tumor followed by the liver.
Another study conducted to investigate the effect of CD inclusion in NPs for drug delivery revealed
the possibility of CD-based SPECT imaging agent [42]. Areses et al. compared the adhesive abilities
and biodistribution of orally administered poly(anhydride) NPs and CD containing NP (CD-NP) in rats
utilizing labeling with 99mTc for SPECT imaging. 99mTc-NP showed activity only in the gastrointestinal
tract on SPECT images, whereas 99mTc-CD-NP revealed extended residence time in stomach: about
13% of 99mTc-CD-NP administered dose and 3% of 99mTc-NP given dose were found in the stomach
after 8 h.
Liu et al., in 2011 [39], studied the improvement of the biodistribution of NPs using CD. Rare-earth
UCNPs were modified by α-CD and OA for increasing of the water-solubility. UCNP-OA-CD
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complexes with Tm inclusion were labeled with 18F (18F-UCNP(Tm)-OA-CD) for microPET imaging of
ex vivo and in vivo biodistribution in mice at 5 min and 2 h. This was the first labeling of CD-based
probe with an 18F. Ex vivo imaging displayed rapid accumulation of NPs in the liver (~90.8% injected
dose(ID)/g) and spleen (~62.5% ID/g) at 5 min and further decreasing of liver uptake to ~57.6% ID/g,
while increased spleen accumulation to 118.9% ID/g after 2 h post-injection. In vivo microPET images
were consistent with ex vivo biodistribution results and showed intense radioactive signals in the liver
and spleen at 5 min after injection.
In addition to the previously discussed reports, a pre-targeted approach for molecular imaging
probe development was presented by Hou et al. [99]. This work was based on biorthogonal
conjugation chemistry between NPs, which have tendency to accumulate in tumors to enhanced
permeability and retention (EPR) effect and radiolabeled imaging agents for PET imaging. One of NPs
components was synthesized from CD-grafted polyethyleneimine (CD-PEI) and trans-cyclooctene
N-hydroxysuccinimide (TCO-NHS), resulted in TCO/CD-PEI building block. Actual tumor-targeting
NP (TCO⊂SNPs) was prepared via self-assembly from four different blocks TCO/CD-PEI, CD-PEI,
adamantane-grafted polyamidoamine (Ad-PAMAM), and Ad-grafted polyethylene glycol (Ad-PEG)
and injected to the tail vein of the mice with U87 glioblastoma cells. After EPR-driven accumulation
in tumor, TCOresulted in TCO/CD-PEI building block. Actual tumor-targeting NP (TCO⊂SNPs
can dynamically disassemble to release TCO/CD-PEI. After 24 h post-injection of TCO⊂SNPs,
freshly prepared tetrazine compound radiolabeled with 64Cu through DOTA (64Cu-Tz) was injected.
Subsequently, distributed 64Cu-Tz can undergo biorthogonal reaction with TCO/CD-PEI parts
left after TCO⊂SNPs disassembling in vivo, yielding the dihydropyrazine conjugation adduct
64Cu-DHP/CD-PEI, which acts as a contrast agent for tumors. Multiple microPET and anatomical
CT images were acquired following the injection of pre-targeted NPs and 64Cu-Tz compound with
in vivo reaction (Figure 10a), along with two series of control PET imaging of a fully ex vivo prepared
64Cu-DHP/CD-PEI adduct (Figure 10b) and free radiolabeled reporter 64Cu-Tz (Figure 10c). Pre-targeted
studies showed the accumulation and retention of radioactivity mainly in the glioblastoma tumor and
liver and some nonspecific uptake by tissues. Supramolecular nanoparticles (SNP) control and probe
(64Cu-Tz) imaging did not present highly distinguishable tumor uptake. Although, high radioactivity
was observed in the liver in all three cases, which can be explained by 64Cu2+ dissociation from DOTA
ligand. This issue can be eliminated by using different radioisotopes for labelling.
Modification of CD by grafting alkyl chains (C6-C14) can lead to self-organization of obtained
derivatives into NPs potentially useful for drug delivery [100]. Further co-nanoprecipitation of
bio-esterified alkylated cyclodextrins with PEGylated phospholipids (PEG) can lead to surface-modified
NPs [101]. Perret et al. researched the effect of the PEG chain length on the plasma protein
absorptivity and blood kinetics of NPs [43]. β-CD derivatives with C10 alkyl chain (β-CD-C10) were
co-nanoprecipitated with PEG with chain length of 2000 (125I-βCD-C10-PEG2000-NP) and 5000 Da
(125I-βCD-C10-PEG5000-NP) and radiolabeled with 125I for SPECT ex vivo and in vivo biodistribution
studies. In vivo SPECT/CT images were acquired at 10 min, 1, 3, 6, and 24h following the injection of NPs
without PEG (125I-βCD-C10-NP) and with PEG (125I-βCD-C10-PEG2000-NP, 125I-βCD-C10-PEG5000-NP).
Hepatic activity was observed with all NPs; however, splanchnic activity was observed only with
125I-βCD-C10-NP. Additionally, 125I-βCD-C10-PEG5000-NP systems showed reduced elimination
and increased circulating concentration following in vivo intravenous injection in comparison with
other NPs.
β-CD-based rotaxane were used in developing theranostic shell-crosslinked NPs (SCNPs) by
Yu et al. for improving drug delivery and controllable release in supramolecular medicine [102].
The core-shell-structured self-assembling NPs were obtained from polyrotaxanes consisted of
amphiphilic diblock copolymer and the primary-amino-containing β-CD (β-CD-NH2), which
undergoes complexation with poly(ε-caprolactone) (PCL) segment. In the gained structure, amphiphilic
deblock copolymer acts as the axle, and β-CD-NH2 acts as a wheel in complex with PCL, whose chains
can experience hydrophobic interactions along with the perylene diimide (PDI) stoppers, which has a
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tendency to π-π stacking interactions. Obtained SCNPs were labeled with radioactive 64Cu through
DOTA attachment to SCNPs (64Cu SCNPs@DOTA) for PET imaging of the dynamic biodistributions
and accumulations of SCNPs in the main organs. HeLa tumor-bearing mice were imaged at various
time-points after intra-venous injection 150 µCi of 64Cu SCNPs@DOTA. Images revealed the high liver
uptake of 64Cu SCNPs@DOTA along with increasing of tumor uptake from the point of injection to
12 h post-injection with further start of clearance at 48 h.
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Another study utilized PET for investigation in vivo distribution of 2-Hydroxypropyl-β-CD
(HPBCD), β-cyclodextrin derivative, and an orphan drug for the Niemann–Pick disease
treatment [40]. Six-deoxy-6-monoamino-(2-Hydroxypropyl)-β-CD (NH2-HPBCD) was conjugated
with p-NCS-benzyl-NODA-GA (NODAGA) and radiolabeled with 68Ga for PET/CT imaging. Ex vivo
and in vivo studies on healthy mice showed that 68Ga-NODAGA-HPBCD was mainly excreted
through the urinary system with low uptake of the abdominal and thoracic organs and tissues at 30
and 90 min post-injection.
The most recent study in the area of CD-based PET molecular imaging probes containing tumor
targeting compounds was done by Trencsenyi et al., in 2019 [41]. Their aims were to develop novel
radiolabeled compound specific to the prostaglandin E2 (PGE2), which plays an important role in
tumor progress and formation of metastases. The high affinity of PGE2 to the randomly methylated
β-CD (RAMEB) was reported by Sauer et al. [103]. Trencsenyi et al., in their research, aimed to
synthesize PGA-specific RAMEB labeled with 68Ga through NODAGA (68Ga-NODAGA-RAMEB)
for investigation of its tumor-targeting properties and in vivo biodistribution using PET. PancTu-1
and BxPC3 tumor-bearing SCID mice were intravenously injected with 68Ga-NODAGA-RAMEB.
The injection was followed with dynamic and static microPET imaging at 0–90 min. The accumulation
of 68Ga-NODAGA-RAMEB was significantly higher in BxPC3 tumors than in the PancTu-1; the highest
post-injection tumor-background ratio (T/M) was obtained at 80–90 min post-injection. The T/M
standardized uptake values (SUVs) were 10-fold lower in the PancTu-1 than those of BxPC3 tumors
confirming the high PGE2 selectivity of 68Ga-lebeled cyclodextrin.
5. CD-Based CT Contrast Agents
The initial development of CD-based contrast agents for CT was used to investigate multimodality
imaging potential of phosphorescent-modified NaDyF4 NPs (DyNPs) [53]. OA-coated DyNPs
underwent complexation with α-CD followed by conjugation with Gd(III)-DTPA complex. The last
stage of contrast agent formation was the loading of phosphorescent Ir(Dbz)2(Pbi) complex with in the
hydrophobic layer of Gd-α-CD-DyNPs [53]. Besides the contrast creation potential for fluorescence
and MRI, Zhou et al. considered the developed Ir-Gd-α-CD-DyNPs as a potential contrast agent
for CT due to the presence of heavy atoms of Dy, Gd, and Ir. The measured Hounsfield units (HU)
value of 10 mg/mL Ir-Gd-α-CD-DyNPs aqueous solution was equal to 158 at 80 kV X-ray energies.
Following in vitro experiments, Ir-Gd-α-CD-DyNPs were used for CT scanning of tumor-bearing mice
(Figure 11). The original HU value of 109 for the tumor increased to 212 HU after intratumoral injection
of 100 ul of 3 mg/mL Ir-Gd-α-CD-DyNPs (Figure 11G) solution. As a result, approximately 100% signal
enhancement was observed on the CT scans.
Another multimodal CD-based contrast agent that was developed for CT scanning was a
core-shell-structured alkali ion-doped CaF2:Yb,Er UCNP [50]. Similar to the NPs discussed above, the
core of NPs was coated with OA with subsequent complexation with α-CD. The final α-CD/UCNPs
contrast agent was compared to well-known iopromide 300 CT clinical contrast agent. Yin et al.
found that developed α-CD/UCNPs have 45% higher HU value at concentration 80 mM/L. This high
X-ray absorption originates from the present high atomic number elements. In addition, investigated
α-CD/UCNPs were loaded with doxorubicin, and the ability of simultaneous cancer imaging and
treatment using this contrast agent was suggested [50].
The next achievement in the CT contrast agent development was obtained in 2017 by conjugating
β-CD to poly(methyl vinyl ether-alt-maleic anhydride) (PVME-alt-MAH) with a subsequent reaction
using modified dextran to create gel microspheres [104]. To make dextran microspheres visible for
CT, they were loaded with iodine in n-hexane. Through the micro-CT phantom imaging, Zhu et al.
observed the subsequent improvement of contrast after iodine loading.
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Another study, conducted in 2017, demonstrated synthesis of β-CD-{poly(ε-caprolactone)-poly
(2-aminoethyl methacrylate)-poly[poly(ethylene glycol) methyl ether methacrylate]}21 (β-CD-(PCL-
PAEMA-PPEGMA)21) with stable unimolecular micelles formed in aqueous solution [51].
β-CD-(PCL-PAEMA-PPEGMA)21 had used a template for the creation of gold NPs (AuNPs) with
uniform sizes, followed by the encapsulation of doxorubicin (DOX). The CT performance of the
final β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX contrast agent was compared to the clinically
available Omnipaque both in vitro and in vivo. At a concentration of 800 uM, Lin et al. found the X-ray
absorption of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX solution to be approximately 23% higher
compared to Omnipaque. In vivo imaging of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX contrast
agent in HepG2 mice tumor model demonstrated significant enhancement of CT signal compared to
the clinical iodine analogue [51].
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Another step in the development of CD-based CT contrast agents was done
by creation an unimolecular micelle system synthesized from 21-arm star-like polymer
β-CD-{poly(lactide)-poly(2-(dimethylamino) ethyl methacry late)-poly[oligo(2-ethyl-2-oxazoline)
methacrylate]}21 (β-CD-(PLA-PDMAEMA-PEtOxMA)21) followed by production of β-CD-(PLA-
PDMAEMA-PEtOxMA)21/AuNPs/DOX [105]. The developed Au-loaded β-CD-based contrast
agent was tested in the animal HepG2 tumor model. Lin et al. found that intravenously
injected β-CD-(PLA-PDMAEMA-PEtOxMA)21/AuNPs/DOX produces substantially higher CT contrast
compared to iodine-based Omnipaque, which was used for control scans.
Following the previous studies, the most recent advance in the field of CD-based CT
contrast agents was achieved by the same group [106]. The authors synthetized 21-arm star-like
polymers β-CD-g-{poly(2-(dimethylamino)ethyl methacrylate)-poly(2-hydroxyethyl methacrylate)-
poly[poly(ethylene glycol) methyl ether methacrylate]} (β-CD-g-(PDMA-b-PHEMA-b-PPEGMA)).
By adding HAuCl4 solution into β-CD-g-(PDMA-b-PHEMA-b-PPEGMA) aqueous solution and
triggering subsequent reduction with DMA, the AuNPs at the core of unimolecular micelles were
formed. The CT contrast of β-CD-g-(PDMA-b-PHEMA-b-PPEGMA)/AuNPs agent was compared
to contrast created by Omnipaque in vitro. Lin et al. found that, at a concentration of 800 uM,
the X-ray attenuation of β-CD-g-(PDMA-b-PHEMA-b-PPEGMA)/AuNPs was approximately 37%
bigger than that of Omnipaque. The developed β-CD-g-(PDMA-b-PHEMA-b-PPEGMA)/AuNPs
demonstrated slightly higher X-ray absorption compared to previously synthetized β-CD-
(PCL-PAEMA-PPEGMA)21/AuNPs [51,106]. However, the average HU values of β-CD-g-(PDMA-b-
PHEMA-b-PPEGMA)/AuNPs at each concentration were slightly lower than previously developed
β-CD-g-(PLA-b-PDMA-b-PEtOxMA)21/AuNPs [105,106].
6. Discussion
Starting in the early 1990s, CDs became of large interest for developing contrast agents and
molecular probes for medical imaging. Although the primary application of CDs in medical imaging
was the basis for developing novel Gd-based MRI contrast agents, CD-based contrast agents commence
to be utilized by other imaging modalities such as PET, CT, US, and PAI. This growing interest is
caused by excellent biocompatibility, low toxicity, and relative ease of modifying of CD molecules.
Currently, the most frequently used CD molecule for contrast agent development is β-CD. Despite
the extensive development of β-CD-based contrast agents, some of the medical imaging areas started
utilizing α- and γ- CD-based contrast agents and molecular probes as well.
The working mechanism of the vast majority of CD-based contrast agents for conventional MRI
relies on the Freed’s theory [57] and the decreasing of the relaxation times of the solvent protons
once either paramagnetic ion or metal–organic complex containing the paramagnetic ion binds to
a supramolecular cage. Initially, this binding was done through hydrophobic interaction between
CDs cavity and metal–organic complexes. Although contrast agents synthesized using this approach
demonstrated significantly better performance compared to the clinically available analogs, the main
disadvantage of this technique is blocking the supramolecular cage cavity, which makes the developed
contrast agents and molecular probes uncapable to image some drug transport, biodistribution, and
treatment monitoring. In addition, the number of paramagnetic ions per molecule is also limited,
since usually only one metal–organic complex enters the cavity. This issue was overcome by creating
different CD-based polymers and dendrimers, and the number of macromolecules determined the
maximum number of paramagnetic ions per molecule. Starting from the early 2000s, the direct labeling
of the CD macrocycles with chelates containing paramagnetic ions has been developed intensively.
This method allows keeping the CD cavity free for interactions with different molecules. Therefore, the
contrast agents based on the direct labeling of the CD macromolecules have a significantly larger field
of applications compared to agents developed using non-covalent interactions.
Currently, CD-based MRI contrast agents contain mostly Gd(III) ions and are designed as T1
contrast agents. On the other hand, the development of CD-based T2 and T2* contrast agents have
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been demonstrated in vitro and in vivo [23,71,75]. Although some of the developed CD-based contrast
agents for proton MRI demonstrated an overall low level of cytotoxicity, dedicated toxicology studies
are needed prior to the further translation of this imaging agents into clinics. In addition, the vast
majority of the relaxivity measurements were conducted at low magnetic fields, which are not for
clinical imaging purposes, such as 0.47 and 0.5 T. The studies that focused on animal imaging were
mostly conducted at high magnetic fields, such as 7 and 9.4 T. In order to facilitate the potential clinical
transition of the developed CD-based contrast agents, the accurate measurement of relaxivities and
comparisons to clinical analogs should be performed at 1.5 and 3 T, which are currently used for clinical
MRI. During the last eight years, CDs drew attention from researchers working with hyperpolarized
MRI. Although only a few studies were conducted, the obtained results demonstrated the high potential
of CD macromolecules to become a basis for further development of hyperpolarized probes. Recently,
Hane et al. demonstrated that γ-CD-based pseudorotaxanes can be a valuable platform for developing
the molecular imaging probes that utilizes the HyperCEST effect [95]. The alkyne chains have a
high affinity to the γ-CD cavity and can be easily designed to serve as a high-affinity probe that has
a selective binding to the disease site. Functionalizing the alkyne chain should be done carefully
such that there is no effect on the interaction with hyperpolarized 129Xe. The HyperCEST depletion
observed was only around 50% indicating partial depolarization of hyperpolarized 129Xe encapsulated
by γ-CD-based pseudorotaxanes. An accurate study for radiofrequency saturation pulses is required to
maximize the HyperCEST depletion and to translate γ-CD-based pseudorotaxanes to in vivo imaging
applications. Although the demonstrated results of hyperpolarized MRI molecular imaging probes
look promising, further in vivo imaging studies are needed, as well as biodistribution and toxicity
evaluations of the proposed biosensors.
Following the success of the CD-based MRI contrast agents, several attempts have been made to
use CDs as a contrast agent for US imaging [44,96]. The developed US CD-based contrast agents caused
significant acoustic impedance difference between the tissue and the contrast agents. Despite successful
in vitro demonstration of this proof-of-principle [44], there was no further development of the CD-based
contrast agent for US imaging purposes during the last five years. On the contrary, CD-coated NPs
became of interest for the PAI. It was found that coating of UCNPs with α-CD cause photoacoustic
signal enhancement [49] and, therefore, can serve as efficient PAI contrast. The most recent achievement
in the field demonstrated PAI detection of prosthetic joint infection usingβ-CD-conjugated indocyanine
green in mice [48]. All studies with CD-based PAI tracers were conducted in small animals. Since the
PAI tracers required irradiation with infrared light to emit ultrasound, further studies should move
to the larger animals in order to evaluate penetration depth of the excitation light and to estimate
the performance of PAI contrast agents prior to clinical translation. Furthermore, the development of
larger pallet of PAI contrast dedicated for specific diseases would be beneficial to facilitate the future
translation into the clinic.
The vast majority of the radiolabeled CDs derivatives were used for PET and SPECT imaging
of the drug delivery and biodistribution in vivo. To be suitable for PET, multiple CD-based tracers
containing 64Cu,68Ga, and 18F were developed. For SPECT imaging purposes, CD macrocycles were
radiolabeled with either 99mTc or 125I. The further widening of the radiolabeled CD derivatives might
become a useful tool for pharmaceutics and drug development.
The most recent CD-based NPs were studied as contrast agents for CT. To be able to produce a
sufficient contrast, the CD-based NPs must contain atoms with a high atomic number. The heavy
atoms absorb X-rays with higher efficiency, increasing the X-ray attenuation coefficient of the tissue
in which the contrast agent is present [107–109]. With modern advances in X-ray detection allowing
lower dose image acquisition [110–113], the utilization of the novel CD-based NPs containing heavy
elements will be highly beneficial for accurate anatomical imaging purposes. In addition, the novel
dual energy CT approach [114,115] will benefit even more from the implementation of the novel
CD-based NPs. Implementation and further development of the demonstrated NPs with substantially
higher X-ray attenuation compared to currently available iodine and barium contrasts could potentially
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allow a superior improvement of CNR of the dual energy CT image. CT contrast of CD-based NPs
was initially observed from contrast agents developed for multimodal imaging [50,53]. Only during
the last three years has the research in synthesis of dedicated CT CD-based contrast agents been
conducted extensively. Currently, the vast majority of the CD-based CT contrast agents were developed
specifically for cancer imaging, whereas only one agent for angiography was developed. Therefore, it
might be potentially useful to develop CD-based contrast agents suitable for different types of clinical
CT imaging. In addition, the potential CD-based CT contrast agents must undergo an accurate toxicity
study prior to further translation to in vivo imaging. Furthermore, special attention should be given
to the investigation of extraction pathways of the contrast agents from the living organism during
in vivo studies.
One of the potential approaches for further advances in the field of CD-based contrast agents is
the development of a contrast agent that can serve for dual imaging modalities such as PET/MRI and
PET/CT. Usually, the PET-active component of the tracer is small, and therefore, the development of
the PET/MRI and PET/CT contrast agents could be built around radiolabeling of the existing CD-based
agents for MRI and CT imaging modalities, respectively.
Overall, CDs are of high interest in the medical imaging field and are currently a very promising
basis for developing various contrast agents. The successful clinical translation of CD-based contrast
agents for proton MRI can help significantly improve the quality of clinical MRI scans. Further
development of functionalized CD-based imaging agents for MRI has the potential to make molecular
imaging using clinical proton MRI possible. Despite the enormous development level of CD-based
contrast agents for conventional proton MRI, other imaging modalities started utilizing CD-based
contrast agents recently and further developments and investigations are needed prior to successful
clinical translation. Nevertheless, CD-based contrast agents demonstrated exceptional performance in
the areas of CT, PET, and PAI.
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